Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera

NCT06828705 | Not Yet Recruiting

• 1 other identifier: 2024PI206
• Study Type: observational
• Target: 300
• Locations: 0 countries
• Sites: N/A

Brief Summary

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

Conditions

Neurodegenerative Diseases

Outcome Measures

Primary Outcomes (1)

• To create the first international database of Datscan by camera VERITON-CT.

  Fixation ratio of central gray nuclei of the brain namely, the global striatum, caudate nuclei, putamens

  One day

Secondary Outcomes (1)

• Compare this database with another database from another type of camera (Lyon nuclear medicine team) to show its superiority.

  One day

Interventions

datscan scintigraphy OTHER

Semi-quantitative analysis on Datscan imaging scintigraphy

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adult patients who have undergone a Datscan® scintigraphy on the VERITON-CT camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, in the absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease

You may qualify if:

• Adult patients who have undergone a Datscan scintigraphy on the VERITON camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, -Absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease.
• The clinical diagnosis can only be established after two years of clinical follow-up.

You may not qualify if:

• Excluded from this research will be the patients opposed to the use of their data, minors, atypical Parkinsonian syndromes,
• patients who died before two years of clinical follow-up,
• patients who had their Datscan examination carried out on a camera other than the VERITON and - patients lost to follow-up.

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

MeSH Terms

Conditions

Neurodegenerative Diseases

Condition Hierarchy (Ancestors)

Nervous System Diseases

Central Study Contacts

Antoine VERGER, MD,PhD

CONTACT

0383153911; a.verger@chru-nancy.fr

Veronique ROCH, MsC

CONTACT

0383154276; v.roch@chru-nancy.fr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prinicipal Investigator

Study Record Dates

• First Submitted: January 31, 2025
• First Posted: February 14, 2025
• Study Start: July 30, 2025
• Primary Completion: August 15, 2025
• Study Completion: November 30, 2025
• Last Updated: July 22, 2025

Record last verified: 2025-07